Septerna, Inc. (NASDAQ:SEPN - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Septerna in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings per share of ($2.14) for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share.
Separately, Wells Fargo & Company raised their price target on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th.
Read Our Latest Analysis on SEPN
Septerna Stock Down 2.3%
SEPN stock traded down $0.24 during trading on Wednesday, hitting $10.17. 299,177 shares of the company's stock traded hands, compared to its average volume of 700,492. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The stock has a fifty day moving average price of $7.97 and a two-hundred day moving average price of $12.31.
Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter.
Hedge Funds Weigh In On Septerna
Several large investors have recently bought and sold shares of SEPN. Tower Research Capital LLC TRC acquired a new stake in Septerna during the 4th quarter valued at $25,000. New York State Common Retirement Fund purchased a new position in shares of Septerna during the 4th quarter valued at $32,000. Legal & General Group Plc bought a new stake in Septerna in the fourth quarter worth $42,000. Summit Investment Advisors Inc. bought a new stake in Septerna in the fourth quarter worth $45,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Septerna in the first quarter worth $49,000.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Read More
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
